Theravance Biopharma, Inc. (TBPH)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 90
- Market Cap
- $873M
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
SentiSense also tracks daily options readings for Theravance Biopharma, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Theravance Biopharma, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.